25
4
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9766 |
GW590735
|
PPAR | DNA Damage/DNA Repair; Metabolism |
GW590735 是一种有效的选择性 PPARα 激动剂,对 PPARα 的 EC50 为 4 nM,比 PPARδ 和 PPARγ 的选择性至少高 500 倍。 GW590735 可用于血脂异常研究。 | |||
T4628 |
Seladelpar
MBX 8025 |
PPAR | DNA Damage/DNA Repair; Metabolism |
Seladelpar (MBX 8025) 是一种有效的,具有口服活性的, 特异性PPAR-δ激动剂,EC50为 2 nM。 | |||
T27719 |
KD-026
SLx 4090,SLx4090,KD026,SLx-4090 |
CETP | Metabolism |
KD-026 (SLx 4090) 是具有口服活性的、肠细胞特异性的微粒体甘油三酯转移蛋白 (MTP)抑制剂,IC50为 8.0 nM。KD-026 (SLx 4090) 在糖尿病2型中有研究的价值。 | |||
T20950 |
MK-8245 analog
MK-8245-analog,MK 8245 analog |
Others | Others |
MK-8245 analog 是 MK-8245 的类似物,MK-8245 是一种肝脏靶向的硬脂酰辅酶 A 去饱和酶 (SCD) 抑制剂。它可用于治疗血脂异常和糖尿病。 | |||
T31083 |
CP-868388 free base
CP868388,CP 868388,(-)-CP-868388,UNII-999KY5ZIGB,CP-868388 |
PPAR | DNA Damage/DNA Repair; Metabolism |
CP-868388 free base (CP-868388) 是一种具有口服活性、有效性和选择性的 PPARα 激动剂,具有降血脂和抗炎活性,可用于研究血脂异常。 | |||
T27439 |
GS-9667
CVT-3619,CVT 3619 |
Adenosine Receptor | GPCR/G Protein; Neuroscience |
GS-9667是一种A(1)腺苷受体(AR)的选择性部分激动剂,通过降低游离脂肪酸(FFA)可有效治疗2型糖尿病(T2DM)和血脂异常。 | |||
T77784 |
WAY-297848
|
Glucokinase | Metabolism |
WAY-297848 是一种新型的 glucokinase 激活剂,可用于预防或治疗高血糖、糖尿病、肥胖症、血脂异常和代谢综合征。 | |||
T35868 |
BCAT-IN-2
|
Others | Others |
BCAT-IN-2 是一种具有口服活性和选择性的线粒体支链氨基转移酶(BCATm)抑制剂,抑制 BCATm 和 BCATc,可用于肥胖症和血脂异常。 | |||
T21587 |
Muraglitazar
Pargluva,BMS-298585 |
PPAR | DNA Damage/DNA Repair; Metabolism |
Muraglitazar (BMS-298585) 是一种 PPAR α/γ的双激动剂,用于治疗2型糖尿病及相关血脂异常。Muraglitazar 对人 PPARα (EC50 = 320 nM)和 PPARγ(EC50 = 110 nM)具有较强的体外活性。 | |||
T27509 |
GW-493838
GW 493838X,GW 493838,GW493838,GW493838X,GW-493838X |
Adenosine Receptor | GPCR/G Protein; Neuroscience |
GW-493838是一种有效的腺苷 A1A 受体激动剂,用于治疗血脂异常和神经性疼痛,对创伤或手术引起的疱疹后神经痛或周围神经损伤具有镇痛效果。 | |||
T38683 |
SCD1 inhibitor-3
SCD1-IN-3,SCD1 inhibitor-3,SCD1 inhibitor 17a |
Dehydrogenase | Metabolism |
SCD1 inhibitor-3 (ML-270) 是一种高效、口服的化合物,可以抑制SCD1,且安全性极高。 SCD1 inhibitor-3 显示出在代谢疾病(包括肥胖、二型糖尿病和血脂异常,以及痤疮和癌症等各种皮肤病)方面的巨大研究潜力。 | |||
T3685 |
SR9009
Stenabolic,REV-ERB Agonist II |
Autophagy | Autophagy |
SR9009 (Stenabolic) 是一种REV-ERBα/β激动剂,可增加由 REV-ERBα/ERBβ 调节的基因的组成性抑制,IC50分别为 670 nM 和 800 nM。 | |||
T71492 |
Atorvastatin strontium
|
||
Atorvastatin strontium is used primarily for lowering blood cholesterol and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.Atorvastatin is also used for the treatment of dyslipidemia. | |||
T15264 |
Exicorilant
CORT 125281 |
Others | Others |
Exicorilant is a selective and oral active glucocorticoid receptor (GR) antagonist (Ki: 7 nM) and it also has the potential to overcome adiposity, glucose intolerance, and dyslipidemia. | |||
T27749 |
KRP-297
KRP297,MK-0767,L410198,L 410198 |
||
KRP297 is a PPAR agonist potentially for the treatment of type 2 diabetes and dyslipidemia. | |||
T27706 |
K-111
BM170744,BM 170744,BM-170744,K111 |
||
K-111 is a PPAR alpha agonist. K-111 improves insulin resistance, reducing bodyweight, and ameliorating atherogenic dyslipidemia. | |||
T62220 |
DGAT1-IN-3
|
||
DGAT1-IN-3 是一种选择性的、有效的,口服具有活力的 DGAT-1 抑制剂,能够抑制人类 DGAT-1 (IC50: 38 nM) 和大鼠 DGAT-1 (IC50: 120 nM)。DGAT1-IN-3 能够用于肥胖、血脂异常和代谢综合征的研究。 | |||
T33415 |
MK 0767
MK0767,MK-0767 |
||
MK 0767 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist that has been investigated as a potential treatment for type 2 diabetes and dyslipidemia. | |||
T71560 | Atorvastatin magnesium trihydrate | ||
Atorvastatin magnesium trihydrate is used primarily for lowering blood cholesterol and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.Atorvastatin is also used for the treatment of dyslipidemia. | |||
T10964L |
DB1976 dihydrochloride
DB1976 hydrochloride,DB1976 2HCl |
Apoptosis; NF-κB | Apoptosis; NF-κB |
DB1976 dihydrochloride (DB1976 2HCl) ,一种转录因子 PU.1 抑制剂,具有潜在抗炎活性,可在体内实验中减缓小鼠的炎症和纤维化,改善了葡萄糖稳态和血脂异常。DB1976 dihydrochloride 促进细胞凋亡,可用于研究代谢功能障碍和非酒精性脂肪性肝炎。 | |||
T80817 |
WAY-328127
|
||
WAY-328127是一种活性分子,适用于生化反应研究。 | |||
T60535 | PPARα/γ agonist 1 | ||
PPARα/γ agonist 1 是一种有效的双重 PPARα/γ部分激动剂,是用于研究血脂异常和糖尿病的有前途的化合物。PPARα/γ agonist 1 对 PPARα 和 PPARγ 的EC50值分别为 28 nM 和 69 nM。 | |||
T63876 |
TRβ agonist 1
|
||
TRβ agonist 1 为一种选择性且对突变敏感的甲状腺激素受体 β (TRβ) 激动剂,其EC50值为21 nM。该化合物适用于血脂异常、非酒精性脂肪性肝炎 (NASH) 与甲状腺激素抵抗 (RTH) 研究。 | |||
T79051 |
PCSK9-IN-15
|
||
PCSK9-IN-15(化合物5)是一种高效PCSK9抑制剂,亲和力强(KD<200 nM)。该化合物与胆固醇代谢相关,可调控低密度脂蛋白胆固醇(LDL-C)水平,适用于研究降低胆固醇及血脂异常。 | |||
T37522 | Teneligliptin | ||
Teneligliptin (MP-513) is a potent chemotype prolylthiazolidine-based DPP-4 inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50s of approximately 1 nM. Teneligliptin (MP-513) inhibits all these DPP-4 enzymes in a concentration-dependent manner. The IC50s of Teneligliptin (MP-513) for rhDPP-4, human plasma, and rat plasma are 0.889, 1.75, and 1.35 nM, respectively. A study of enzyme inhibition kinetics is conducted for Teneligliptin (M... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T7992 |
4-Hydroxyflavanone
|
NO Synthase | Immunology/Inflammation |
4-Hydroxyflavanone 是一种黄酮的合成类似物,是 SREBP 成熟和脂质合成的抑制剂。它具有研究肝脏脂肪变性及血脂异常的潜力。 | |||
T3324 |
Lycorine
Galanthidine,Narcissine,石蒜碱,Amarylline,Belamarine,Licorine,番石榴碱 |
Apoptosis; Virus Protease; Antibacterial; AChR; Fatty Acid Synthase | Apoptosis; Metabolism; Microbiology/Virology; Neuroscience |
Lycorine (Narcissine) 是从金眼科植物科中提取的一种天然生物碱。它是一种具有口服活性的SCAP 抑制剂,Kd 值 15.24 nM。它也是黑色素瘤血管生成抑制剂,有用于前列腺癌和代谢疾病的研究潜力。 | |||
T5S2178 |
Fargesin
辛夷脂素,(+/-)-Fargesin |
Adrenergic Receptor | GPCR/G Protein; Neuroscience |
Fargesin ((+/-)-Fargesin) 是一种活性新木脂素,从木兰植物中分离得到,具有抗高血压和抗炎活性。 | |||
T73074 | Phanginin A | ||
Phanginin A 是有效的口服活性SIK1激活剂,通过抑制糖异生、增加p-SIK1表达及降低p-CREB表达,达到降低血糖水平、改善葡萄糖耐量和血脂异常的效果,显示出其在2型糖尿病研究中的潜力。 |